EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PARPi, BRCA, and gaps: controversies and future research

Diego Dibitetto, Carmen A Widmer, Sven Rottenberg

Trends in Cancer · 2024-09 · 10 (9) · 857-869

DOI: 10.1016/j.trecan.2024.06.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2024-09. Verfasst von Diego Dibitetto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Länggassstrasse 122, 3012 Bern, Switzerland; Bern Center for Precision Medicine…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, BRCA2 Protein, BRCA1 Protein. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, various poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been approved for the treatment of several cancers to target the vulnerability of homologous recombination (HR) deficiency (e.g., due to BRCA1/2 dysfunction). In this review we analyze the ongoing debates and recent breakthroughs in the use of PARPis for BRCA1/2-deficient cancers, juxtaposing the 'double-strand break (DSB)' and 'single-stranded DNA (ssDNA) gap' models of synthetic lethality induced by PARPis. We spotlight the complexity of this interaction, highlighting emerging research on the role of DNA polymerase theta (POLθ) and ssDNA gaps in shaping therapy responses. We scrutinize the clinical ramifications of these findings, especially concerning PARPi efficacy and resistance mechanisms, underscoring the heterogeneity of BRCA-mutated tumors and the urgent need for advanced research to bridge the gap between laboratory models and patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinBRCA1 ProteinHumansNeoplasmsDNA Polymerase thetaDNA-Directed DNA PolymeraseDNA, Single-StrandedDNA RepairDNA Breaks, Double-StrandedDrug Resistance, NeoplasmAnimalsHomologous RecombinationSynthetic Lethal Mutations

Stichwörter der Autor:innen

BRCADNA damagePARP inhibitorscancergapshomologous recombination

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanBRCA1 protein, humanDNA Polymerase thetaDNA-Directed DNA PolymeraseDNA, Single-Stranded

Autor:innen und Institutionen

  • Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Länggassstrasse 122, 3012 Bern, Switzerland; Bern Center for Precision Medicine and Cancer Therapy Research Cluster, Department for Biomedical Resear…

Zitieren

APA

Dibitetto, D., Widmer, C. A., & Rottenberg, S. (2024). PARPi, BRCA, and gaps: controversies and future research. Trends in Cancer, 10(9), 857-869. https://doi.org/10.1016/j.trecan.2024.06.008

Vancouver

Dibitetto D, Widmer CA, Rottenberg S. PARPi, BRCA, and gaps: controversies and future research. Trends in Cancer. 2024;10(9):857-869. doi:10.1016/j.trecan.2024.06.008

BibTeX
@article{Dibitetto2024,
  author = {Dibitetto, Diego and Widmer, Carmen A and Rottenberg, Sven},
  title = {PARPi, BRCA, and gaps: controversies and future research},
  journal = {Trends in Cancer},
  year = {2024},
  volume = {10},
  number = {9},
  pages = {857--869},
  doi = {10.1016/j.trecan.2024.06.008}
}
Kostenlos starten →